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ABSTRACT (200 words)
Background and aims: Non invasive approaches are useful to differentiate simple steatosis from nonalcoholic steatohepatitis (NASH) in obese and morbidly obese patients. The aim of this study was to develop a new scoring system to diagnose definitive NASH.
Methods: Preoperative clinical and biological data including serum caspase 3-generated cytokeratin-18 fragments (CK18) and peroperative liver biopsies were obtained from 464 morbidly obese patients who had undergone bariatric surgery. The cohort was divided into two groups: training group (n=310) and validation group (n=154). Definitive NASH was defined according to Kleiner's classification with a NAFLD Activity Score (NAS) ≥5.
Results: Alanine aminotransferase (ALT), CK18 fragments and the presence of metabolic syndrome (MS) were independent predictors for discriminating patients with NAS ≥5 in the training group. These three parameters were used to carry out a scoring system for the prediction of NAS ≥5. Whereas serum CK18 fragment alone had an Area under the Receiver Operating Characteristic (AUROC) curve = 0.74, AUROC curves of the scoring system were 0.88 and 0.83 in the training and in the validation group respectively.
Conclusion:
A simple and non invasive composite model including MS, ALT and CK18 fragments was able to accurately predict NAS ≥5 in morbidly obese subjects. 
MAIN TEXT
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of pathological liver abnormalities ranging from pure steatosis to non-alcoholic steatohepatitis (NASH), and finally to severe fibrosis and cirrhosis. 1 Classically, pure steatosis has a relatively good prognosis whereas steatohepatitis is associated with progression of liver fibrosis. 2, 3 Thus, differentiation of these two states is important.
NAFLD is common in the context of morbid obesity and NASH can be present in 20−40% of these patients. 4, 5 The mechanisms of NAFLD development are complex and poorly understood. Chronic low grade chronic inflammation, adipokines dysregulation and insulin resistance in the liver and visceral adipose tissue are the major contributing factors. 6, 7 NAFLD has been considered as the hepatic manifestation of so-called "metabolic syndrome"(MS), a syndrome highly related to morbid obesity with its well defined components: increased waist circumference, high blood pressure, high blood triglycerides, low blood high-density lipoprotein (HDL) cholesterol, and high blood glucose level. 5, [8] [9] [10] Hepatocyte apoptosis may also play an important role in the liver injury and disease progression in NAFLD.
11
Liver biopsy is still considered the gold standard to assess hepatic pathology in most chronic liver diseases, including NAFLD, but it is an invasive technique. Moreover, liver biopsy is associated with sampling and inter-observer variability, which might explain the differences in prevalence of NASH in morbidly obese patients reported in previous studies. 4, 12, 13 In addition, the large number of patients with morbid obesity exposed to NAFLD renders systematic liver biopsy in all patients difficult. The availability of a non-invasive test would allow systematic diagnosis in this particularly predisposed subpopulation and would enable repeated assessment during the follow-up in a more feasible way than liver biopsy. Unfortunately, medical imaging techniques (ultrasound, computerized tomography and magnetic resonance imaging) fail to differentiate pure steatosis from NASH. 14 Moreover, echography in severely or morbidly obese patients is frequently of poor quality.
Several non-invasive scoring models using routine clinico-biological parameters have been proposed for the diagnosis of NASH, but most of them have not been thoroughly validated. [15] [16] [17] [18] [19] Recently, apoptotic caspase-3 generated cytokeratin 18 (CK18) fragments in the blood were reported to predict histological NASH in cohorts of obese patients or in patients with insulin resistance. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   4 The aim of this study was to develop a scoring system to diagnose definitive NASH using clinical and biological data related to the metabolic syndrome and liver injury including caspase-3 generated CK18 fragment, in a large cohort of European morbidly obese patients.
20-23
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Pathological liver assessment
Hepatic wedges were obtained during bariatric surgery. Surgical liver biopsies were reviewed by two liver pathologists (MC-SP and SP) without knowledge of the clinical or biological characteristics of the patients. Routine haematoxylin-eosin-safran and sirius red staining were performed on all biopsies. All biopsies were graded according to the NAFLD Activity Score (NAS). This score classifies patients as simple steatosis (NAS≤2), borderline group (3≤NAS≤4) or definitive NASH (NAS≥5). 26 Patients were analyzed as with or without NAS ≥5.
Liver bridging fibrosis was assessed by sirius red staining and was classified into five stages as follows: absent, mild, moderate (incomplete septa), severe (with complete septa) and cirrhosis.
Statistical analysis
Statistical analysis was first performed on the training patient cohort (n=310) in three steps: (i) univariate analysis of clinical and biochemical parameters was carried out for patients with NAS <5 and was established for the model score; this value maximized the sum of the sensitivity and specificity to identify patient status. The diagnostic accuracy of the logarithmic transformation of the Nice Model (Prob(Y<>group) = 1/(1+Exp(-Nice Model)) was then determined. Sensitivity, specificity, positive predictive value, negative predictive value and likelihood ratio were determined for each cutoff value of the NiceModel.
Statistical analysis was then carried out on the validation patient cohort (n=154). The main parameters of both cohorts were compared using Chi 2 test or Fischer's exact tests for nominal data, and by two-sample t tests for continuous data. The final model obtained in the training patient cohort was applied to the validation patient cohort. The diagnostic performance of the model was determined by constructing a ROC curve and calculating the AUROC curve for prediction of patients with NAS ≥5.
All statistical analyses were performed using NCSS 2007 software. 
Results
Pathological findings and univariate analysis
The distribution of NAS scores among the 310 patients in the training patient cohort is shown in the table 1. Using Kleiner's classification, 39 patients had NAS ≥5. Fibrosis reported using bridging fibrosis grade was absent in 13 patients, mild perivenular and/or periportal fibrosis in 281, septal fibrosis in 15 patients and severe fibrosis in one patient.
Using the univariate analysis (Table 2) , patients with NAS ≥5 had higher waist circumference, ALT, γGT, triglyceride levels, blood glucose levels, C peptide, glycosylated hemoglobin, HOMA-IR, ferritin and CK18 fragment levels compared to patients with NAS <5. HDL-cholesterol was lower in the more severe patients. Rates of type 2 diabetes mellitus and MS were also higher in patients with NAS ≥5 (Table 2 ). Neither age nor body mass index (BMI) were associated with NAS ≥5.
Multivariate analysis
Multivariate analysis included a model combining ALT, γGT, HOMA-IR, CK18 fragment levels, p=0.044) were the only independent variables when NAS ≥5 was the judgment criterion (Table 3) .
CK18 fragments, ALT and IDF metabolic syndrome for the prediction of NAS ≥5
AUROC curves for CK18 fragments, ALT and MS were assessed for the prediction of liver disease (NAS ≥5) in the training patient cohort. The AUROC curves were 0.74, 0.78 and 0.74 for the CK18 fragment levels, ALT and MS respectively for the prediction of NAS ≥5. The distribution of values from the Nice Model according to liver histology in the training patient cohort is shown in Figure 2 . Box plots were constructed either separating patients into simple steatosis (NAS≤2), borderline group (3≤NAS≤4) or definitive NASH (Figure 2A ) or between NAS ≥5 and NAS <5 ( Figure 2B ). Nice Model values were significantly higher in patients with NAS ≥5 compared to borderline (p<0.00001) and to simple steatosis groups (p<0.00001). Nice Model values in the borderline group were also significantly higher than in the simple steatosis group (p<0.00001). In the same way, patients with NAS ≥5 had significantly higher Nice Model values compared to patients with NAS <5 (P<0.0001).
Model to predict NAS ≥5 in morbidly obese patients
Evaluation of the Nice Model in the validation cohort of morbidly obese patients
The training patient and validation patient cohort were similar in terms of age, gender, BMI, ALT, CK18 fragment levels, prevalence of MS, as shown in Table 5 . The number of patients with NAS ≥5
was also similar in the two cohorts (12.6% versus 9%, P=NS). AUROC curves for the prediction of NAS≥5 was 0.83 ( Figure 1 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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Discussion
We propose a new composite scoring system (Nice Model) based on ALT, CK18 fragment levels and the presence of MS to diagnose NAS ≥5 in morbidly obese patients. Indeed, the ALT, CK18 fragment levels or presence of MS separately were moderately predictive of NAS ≥5. The association of these three items in the Nice Model displayed an AUROC for NAS ≥5 of 0.88 and 0.83 in the training (n=310) and in the validation (n=154) cohort of morbidly obese patients respectively.
Assessment of CK18 fragment levels has recently been proposed as a marker for NASH in patients exposed to NAFLD. The value of this marker was suggested by a pilot study and was confirmed in a large multicentre study in obese patients. 20, 27 The disadvantage of the assessment of CK18 fragment levels is that it is not performed routinely in daily practice, but it has the advantage that it is a commercial ELISA kit. The CK18 fragment levels have also been studied in morbidly obese patients.
In a cohort of 99 morbidly obese patients, CK18 fragment levels were found to be associated with NASH. CK18 fragment levels AUROC curve was 0.88. 21 This value was higher than the one found in our training patient group (AUROC curve value only of 0.74) to predict NAS ≥5. Difference in the diagnostic accuracy could be due to the influence of fibrosis on the CK18 fragments levels. As reported by the previous authors CK18 fragments levels were significantly higher in subjects with moderate to severe fibrosis versus those with no or mild fibrosis. 21 In order to improve the prediction of definitive NASH, we attempted to develop a new scoring system combining variables significantly associated with NAS ≥5 in univariate and multivariate analysis.
These variables were CK18 fragment levels, ALT and the presence of metabolic syndrome. ALT level has previously been related to inflammatory liver damage during NASH in morbidly obese patients and to an elevated risk of appearance of MS, diabetes and cardiovascular events. 17, 28 However, ALT alone would not be sufficient for predicting NASH because it has been reported normal levels of transaminases in patients with proven steatohepatitis and/or significant or severe fibrosis due to NASH.
29-31
Presence of Metabolic syndrome in our model is not surprising because it is strongly associated with liver complications. However, in our cohort, metabolic syndrome alone is poorly predictive of definitive NASH. One of the weaknesses of this study is that our model is developed among morbidly obese patients.
The clinical utility of this model will be fully acquired only when a validation on overweight and simple obese patients will have been carried out. Another point is the relatively small number of patients with NAS≥5 which could limit the statistical power of analyses.
Pure steatosis had classically a relatively good prognosis whereas steatohepatitis was associated with liver fibrosis. However, it was recently suggested that patients with low NAS could develop NASH and fibrosis progression. 32 Even if patients with definitive NASH could have a more severe prognosis, clinicians should keep in mind that all patients with NAFLD should undergo periodic assessment and treatment.
In conclusion, a new composite model, the Nice Model, for the diagnosis of definitive NASH in morbidly obese patients based on ALT and CK18 fragment levels and on the presence of a MS is proposed. The diagnostic accuracy of this model was better than using CK18 fragment levels, ALT and the presence of a MS alone. Possibility of the Nice Model to be an alternative to liver biopsy in the follow up of obese patients and in the evaluation of treatments aimed at preventing the progression of liver disease in these high risks patients should be assessed. The identification of non invasive scoring system independent of the severity of obesity and the ethnicity constitute an important challenge for the diagnosis of NASH. 
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It is a prospective study.
Test methods 7
The reference standard and its rationale. Systematic liver biopsy which is the Gold Standard for NASH 8
Technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard.
Yes, page 5 and 6 9 Definition of and rationale for the units, cut-offs and/or categories of the results of the index tests and the reference standard.
"Definitive NASH" (NALFD Activity Score ≥5) was retained according to Kleiner's classification. 10 The number, training and expertise of the persons executing and reading the index tests and the reference standard.
All liver biopsies were read by a specialized pathologist (MCSP). Kleiner's classification was secondly determined by MCSP and SP. 11 Whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.
Yes, the readers of the liver biopsy were blind to the results of the proposed model. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Not done.
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RESULTS
Participants 14
When study was performed, including beginning and end dates of recruitment.
Page 5 15
Clinical and demographic characteristics of the study population (at least information on age, gender, spectrum of presenting symptoms). Table 1 and table 5 16
The number of participants satisfying the criteria for inclusion who did or did not undergo the index tests and/or the reference standard; describe why participants failed to undergo either test (a flow diagram is strongly recommended).
All the patients satisfying the criteria for inclusion were enrolled in the study.
Test results 17
Time-interval between the index tests and the reference standard, and any treatment administered in between.
Clinical and biological data were collected few days before the bariatric sugery after overnight fasting. Liver biopsy was done during surgery.
18
Distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition.
Among morbidly obese patients enrolled in the training cohort 12.6% had a "definitive NASH" (NALFD Activity Score ≥5) 19 A cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the reference standard; for continuous results, the distribution of the test results by the results of the reference standard.
The distribution of the test results by the results of liver biopsy is presented in Figure 2 . ALT level and Metabolic syndrome determination are done routinely. Blood levels of apoptotic caspase-3 generated CK18 fragment levels were measured using a commercial kit. External validation in non morbidly obese patients will be necessary. Pages 10 & 11. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
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